NCT03019471 Non Invasive Cancer Test (NICT): a Proof of Principle Study.
| NCT ID | NCT03019471 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht University Medical Center |
| Condition | Neoplasmata |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2016-03-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2016-03-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators aim to collect tumor DNA out of blood of cancer patients. If this is successful this could lead to the development of a cancer test in blood in the future, which is less invasive than current diagnostic methods.
Eligibility Criteria
Inclusion Criteria: 1. Patients with newly diagnosed local or metastatic breast cancer, colorectal cancer, non-small cell lung cancer and anaplastic glioblastoma, before start of radiation therapy, chemoradiation or chemotherapy. 2. Patients age \> 18 years, willing and able to comply with the protocol as judged by the investigator with a signed informed consent Exclusion Criteria: 1. Patients with a history of malignant disease other than the disease under study, with an exception for adequately treated squamous cell carcinoma of the skin, basal cell carcinoma of the skin and in situ cervix carcinoma. 2. Pregnancy
Contact & Investigator
Christine C. De Die-Smulders, Prof. dr.
PRINCIPAL INVESTIGATOR
Clinical Geneticist in MUMC+
Frequently Asked Questions
Who can join the NCT03019471 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasmata. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03019471 currently recruiting?
Yes, NCT03019471 is actively recruiting participants. Contact the research team at m.macville@mumc.nl for enrollment information.
Where is the NCT03019471 trial being conducted?
This trial is being conducted at Maastricht, Netherlands.
Who is sponsoring the NCT03019471 clinical trial?
NCT03019471 is sponsored by Maastricht University Medical Center. The principal investigator is Christine C. De Die-Smulders, Prof. dr. at Clinical Geneticist in MUMC+. The trial plans to enroll 40 participants.